Medigen Vaccine Biologics Corporation reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 2.09 million compared to TWD 1,246.9 million a year ago. Net loss was TWD 309.26 million compared to net income of TWD 680.21 million a year ago. Basic loss per share from continuing operations was TWD 0.95 compared to basic earnings per share from continuing operations of TWD 2.13 a year ago. Diluted loss per share from continuing operations was TWD 0.95 compared to diluted earnings per share from continuing operations of TWD 2.12 a year ago. Basic loss per share was TWD 0.95 compared to basic earnings per share of TWD 2.13 a year ago. Diluted loss per share was TWD 0.95 compared to diluted earnings per share of TWD 2.12 a year ago.
For the nine months, sales was TWD 341.31 million compared to TWD 1,250.97 million a year ago. Net loss was TWD 757.42 million compared to net income of TWD 344.54 million a year ago. Basic loss per share from continuing operations was TWD 2.35 compared to basic earnings per share from continuing operations of TWD 1.08 a year ago. Diluted loss per share from continuing operations was TWD 2.35 compared to diluted earnings per share from continuing operations of TWD 1.07 a year ago. Basic loss per share was TWD 2.35 compared to basic earnings per share of TWD 1.08 a year ago. Diluted loss per share was TWD 2.35 compared to diluted earnings per share of TWD 1.07 a year ago.